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Abstract
Aims/hypothesis Outcome data on individuals with diabetic
foot ulcers are scarce, especially in those with peripheral arterial
disease (PAD). We therefore examined the clinical character-
istics that best predict poor outcome in a large population of
diabetic foot ulcer patients and examined whether such
predictors differ between patients with and without PAD.
Methods Analyses were conducted within theEURODIALE
Study, a prospective cohort study of 1,088 diabetic foot ulcer
patients across 14 centres in Europe. Multiple logistic
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DOI 10.1007/s00125-008-0940-0regression modelling was used to identify independent
predictors of outcome (i.e. non-healing of the foot ulcer).
Results After 1 year of follow-up, 23% of the patients had
not healed. Independent baseline predictors of non-healing
in the whole study population were older age, male sex, heart
failure, the inability to stand or walk without help, end-stage
renal disease, larger ulcer size, peripheral neuropathy and
PAD. When analyses were performed according to PAD
status, infection emerged as a specific predictor of non-
healing in PAD patients only.
Conclusions/interpretation Predictors of healing differ be-
tween patients with and without PAD, suggesting that
diabetic foot ulcers with or without concomitant PAD should
be defined as two separate disease states. The observed
negative impact of infection on healing that was confined to
patients with PAD needs further investigation.
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ABPI ankle–brachial pressure index
ESRD end-stage renal disease
NYHA New York Heart Association
OR odds ratio
PAD peripheral arterial disease
PNP peripheral neuropathy
Introduction
Diabetic foot ulcers are a common and much feared
complication of diabetes, with recent studies suggesting that
thelifetimeriskofdevelopingafootulcerindiabeticpatients
maybeashighas25%[1]. Foot ulceration requires long and
intensive treatment, has important effects on quality of life
of both patients and care-givers [2] and is associated with
major healthcare costs [3–5]. Although in recent years
much effort has been put into the development of
international guidelines in order to stimulate the delivery
of uniform and structured care [6], prospective data on
outcomes and predictors of outcome in patients with
diabetic foot ulcers are limited.
The population of diabetic patients who present with
foot ulceration is heterogeneous: although most patients
have peripheral polyneuropathy, there are several other
characteristics that may vary among patients, such as the
presence of peripheral arterial disease (PAD), infection and
co-morbidities. PAD is present in approximately one-half of
all patients with foot ulcers [7] and is considered an
important predictor of outcome [8, 9]. Therefore, outcome
data on this important subgroup of patients with diabetic
foot disease are needed. Such a requirement is underlined by
the fact that although diabetic foot ulcers are usually
reported and analysed as one clinical entity, marked differ-
ences in patient, foot and ulcer characteristics can exist
between patients with and without PAD [7]. These obser-
vations raise the question of whether predictors of outcome
in patients with and without PAD may differ.
The aim of the present study was therefore: (1) to obtain
prospective data on outcome of individuals presenting with a
new diabetic foot ulcer, including patients both with and
without PAD; (2) to assess clinical characteristics that best
predictpoor outcome (i.e. non-healing of thefoot ulcer) from
this large set of patients; and (3) to examine whether such
predictors differ between patients with and without PAD.
Methods
Study design and population
The EURODIALE consortium is an international collabora-
tive network that was created to stimulate further research in
the field of diabetic foot disease. Its main objective was to
assess outcome and the major predictors of clinical outcome
in a large sample of European patients with diabetic foot
ulcers. The design and rationale of this study have been
described in detail elsewhere [10].
Briefly, between 1 September 2003 and 1 October 2004,
1,232 patients with a new foot ulcer were included in 14
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748 Diabetologia (2008) 51:747–755diabetic foot centres in ten European countries. The mean
(range) number of included patients per centre was 88 (40–
125). All participating centres have a longstanding expertise
in the field of diabetic foot disease. Patients included were
those presenting for the first time with a new foot ulcer
within a period of 12 months, either at the outpatient or
inpatient clinics of participating centres. Excluded patients
were those who had been treated at the participating centres
for an ulcer on the ipsilateral foot during the previous
12 months and those with a life expectancy of less than
1 year. Participants attended follow-up visits on a monthly
basis. At baseline and during all follow-up visits, data were
collected and recorded on standardised case record forms.
This was done by dedicated investigators in each centre who
were trained during plenary meetings and on-site visits. Re-
corded data included demographics, data on co-morbidities
and foot and ulcer characteristics, as well as management.
The local ethics committees of the 14 hospitals approved the
study protocol and all patients gave written informed
consent.
Management of diabetic foot ulcer
All patients were treated according to protocols based on the
International Consensus on the Diabetic Foot [11], which
include off-loading, diagnosis and treatment of infection,
assessment of vascular status, treatment of PAD and regular
wound debridement.
Potential predictive factors
Potential determinants of healing were chosen onthe basis of
(1) current literature; (2) expert opinion after extensive
discussions during EURODIALE meetings; and (3) suitabil-
ity for use in daily clinical practice. In addition to sex, age at
baseline and duration of diabetes, several disease-specific
characteristics and co-morbidities were investigated [10].
Ulcer characteristics All patients underwent a standardised
examination according to the PEDIS system. This was
developed by the International Consensus on the Diabetic
Foot to enable classification of patients for clinical research
purposes [11, 12] and classifies foot ulcers according to five
categories: perfusion, extent, depth, infection and sensation.
Perfusion assessment included evaluation of the presence
of pedal pulses and measurement of the ankle–brachial
pressure index (ABPI) using a handheld Doppler device;
PAD was considered to be present if ABPI was <0.9 and/or
two foot pulses were absent.
Extent (i.e. size) was determined by multiplying the
largest by the second largest diameter perpendicular to the
first and divided into three categories: <1 cm
2,1 –5c m
2 and
>5 cm
2.
Depth was described as either deep or superficial if a full
thickness lesion of the skin was or was not extending
through the subcutis, respectively.
Infection was diagnosed if two or more of the following
signs were present: frank purulence, local warmth, ery-
thema, lymphangitis, oedema, pain, fever and foul smell.
The term infection covers both soft tissue infection and
bone infection.
Evaluation of sensation (peripheral neuropathy [PNP])
included pressure sensation (10 g monofilament on plantar
aspect of hallux, metatarsophalangeal joints 1 and 5), tactile
sensation (cotton wisp on dorsum of foot), vibration
sensation (128 Hz tuning fork on dorsum of the hallux) and
blunt/sharp discrimination (dorsum of foot). PNP was
diagnosed if the results of two or more of the aforementioned
tests were abnormal.
In addition, the location of the ulcer was divided into
plantar (on the plantar toes, plantar mid- or forefoot and
plantar hind foot) and non-plantar (on the dorsal or
interdigital part of the toes, on the dorsal or lateral aspect
of the foot and heel ulcers). Ulcer duration was divided into
three categories: <1 week, between 1 week and 3 months,
and >3 months.
Co-morbidities The following disabling co-morbidities
were assessed: presence of severe visual impairment (de-
fined as the inability to read a newspaper after correction),
end-stage renal disease (ESRD) (defined as dependency on
haemodialysis or peritoneal dialysis or a previous renal
transplant procedure), heart failure (New York Heart
Association [NYHA] classification III or IV), any neurolog-
ical disorder (excluding diabetic polyneuropathy) resulting
inloss ofmotoror sensory function(e.g. stroke) andinability
to stand or walk without help.
Study main outcome
Main outcome was complete healing (with or without minor
amputation) of the foot, within the maximum follow-up
period of 1 year. Healing was defined as healing (intact skin)
of the whole foot at two consecutive visits. If more than one
ulcer was present, the foot was defined as healed once all
ulcers were healed. Outcome information was not obtained
in 144 patients (11.7% of the patients included) who dropped
out of the study and were therefore excluded from the
analyses. Reasons for dropout were non-compliance (n=24),
inability to follow the patient (lack of transportation, no
social support, too sick to attend; n=25) or if care had been
taken over by other specialists (n=29); in 66 patients the
reason for dropout could not be discovered. At baseline
these participants were slightly older and had a higher
incidence of heart failure, deeper ulcers and ulcers of longer
Diabetologia (2008) 51:747–755 749duration than those included in the analyses (n=1,088;
Table 1).
Statistical analyses
All statistical analyses were carried using the STATA
software package version 9.2 (STATA, College Station, TX,
USA). Comparisons between groups’ characteristics were
made with χ
2 tests (frequency data) or Student’s t test
(continuous data).
Multiple imputation of missing values of predictor
variables Values for one (n=188), two (n=35) or three
(n=13) predictor variables were not available for 236
participants; the number of missing values per predictor
ranged from 0 to 6%. In order to decrease bias and increase
power of the analyses [13], we used multiple imputation
chained equations (procedure ‘ICE’ in STATA) to impute
those missing values (1.7% of all required values) rather than
performing complete case analyses [14, 15]. With ICE the
imputation model of a single variable uses all the other
variables as predictors by appropriate regression models (i.e.
linear, logistic or multinomial if imputed variable is
continuous, dichotomous or categorical). We generated five
imputed datasets that were used to fit the regression models
of interest (in each dataset and in the final, i.e. the combined
dataset). Parameter estimates and standard errors were
combined across the five replicates according to the
procedure described by Rubin [16] and Carlin et al. [17]
(procedure ‘micombine’ in STATA).
Development of predictive models First, univariable logistic
regression analyses were performed for all potential predic-
tor variables with the outcome of interest (non-healing), with
values presented as univariable odds ratios (ORs) along with
the respective 95% CI. Second, all potential predictors were
entered simultaneously in a multivariable logistic regression
model that was reduced to a most parsimonious model using
a backward selection method based on Akaike’s Information
Criterion. These models yielded a set of variables that best
predict (and can be regarded as independent predictors of)
outcome.
Results
Clinical outcome
Within the 1 year follow-up, 77% of the 1,088 patients
healed, 12% were still undergoing treatment, 5% underwent
Table 1 Baseline characteris-
tics of participants included
and those excluded (dropouts)
from the present study
Unless otherwise stated, data
are mean values±SD
aPercentages may not sum to
100 due to missing information
Variable Included (n=1,088) Dropouts (n=144) p value
Age (years) 64.7±12.5 68.0±11.6 0.003
Male sex, n (%)
a 703 (64.6) 85 (59.0) 0.189
Duration of diabetes, n (%)
a 0.418
<5 years 148 (14.1) 19 (13.5)
5–10 years 169 (16.1) 17 (12.1)
>10 years 731 (69.8) 105 (74.5)
Deep ulcer, n (%)
a 476 (43.8) 80 (55.6) 0.007
Size of ulcer, n (%)
a 0.843
<1 cm
2 403 (37.2) 50 (35.0)
1–5c m
2 563 (52.0) 76 (53.1)
>5 cm
2 117 (10.8) 17 (11.9)
Duration of ulcer, n (%)
a <0.001
<1 week 184 (17.0) 10 (7.0)
1 week–3 months 627 (58.1) 68 (47.6)
>3 months 269 (24.9) 65 (45.5)
Plantar location, n (%)
a 493 (48.2) 62 (46.3) 0.675
Pretibial oedema, n (%)
a 197 (18.2) 29 (20.3) 0.538
Heart failure NYHA III–IV, n (%)
a 117 (10.9) 23 (16.1) 0.065
Neurological disorder, n (%)
a 70 (6.5) 9 (6.3) 0.918
Inability to stand or walk without help, n (%)
a 107 (9.9) 15 (10.4) 0.843
Visual impairment, n (%)
a 164 (15.3) 19 (13.2) 0.507
ESRD, n (%)
a 63 (5.8) 7 (4.9) 0.639
Polyneuropathy, n (%)
a 826 (78.5) 105 (76.1) 0.515
Infection, n (%)
a 591 (57.2) 82 (61.2) 0.380
PAD, n (%)
a 505 (47.5) 78 (56.1) 0.056
750 Diabetologia (2008) 51:747–755a major (i.e. above the ankle level) amputation and 6% died
(before healing of the foot ulcer). Among the patients who
healed, 17% underwent a minor amputation; this rate was
similar to that in those patients who did not heal (20%,
p=0.425).
When stratifying patients according to the presence or
absence of PAD, significantly (p<0.001) worse healing
rates were observed in patients with than in those without
PAD (69% vs 84%, respectively). Major amputation and
mortality rates were also higher in patients with (8% and
9%, respectively) than in patients without PAD (2% and 3%
respectively; p<0.001). Baseline characteristics of patients
with PAD compared with those without PAD are provided
in Table 2.
Predictors of healing
Table 3 shows the univariable associations of the
potential predictors of non-healing in the overall popula-
tion and Table 4 presents the variables retained in the
predictive models after backward selection in the com-
bined imputed datasets. The estimates were similar to those
obtained in the complete cases dataset (n=854) indicating
that missing values were non-selective (data not shown).
These include the following eight characteristics, all of
which predict lower probabilities of healing: older age,
male sex, larger ulcer size, heart failure, inability to stand
or walk without help, ESRD, PNP and PAD. These
variables were consistently identified in all five imputed
datasets.
Since we hypothesised that, from an aetiological
point of view, predictors of non-healing would differ
between patients with and those without PAD, predictive
models were also fitted for these two groups separately
(Table 4). In patients with PAD almost all of the predictors
identified in the whole study population, with the excep-
tion of PNP, were again found to be independent predictors
of healing. In addition, the presence of infection emerged
as an additional independent predictor of non-healing. In
patients without PAD, older age, larger ulcer size, inability
to stand or walk without help, ESRD, PNP and, in
addition, longer ulcer duration were independent predictors
of poorer healing.
The observed interaction between infection and PAD
status partly supports the classification of foot ulcer disease
into four stages as suggested by Armstrong et al. (University
of Texas classification system) [9]. Accordingly, upon
analysis of the odds of non-healing per PAD × infection
status, it was only in those patients with both PAD and
infection that the odds of non-healing were markedly
Table 2 Patients’ baseline
characteristics according
to their PAD status
Unless otherwise stated, data
are mean values±SD
aPercentages may not sum to
100 due to missing information
Variable Patients with PAD
(n=505)
Patients without PAD
(n=558)
p value
Age (years) 69.1±11.2 60.5±12.3 <0.001
Male sex, n (%)
a 321 (65.6) 366 (63.6) 0.490
Duration of diabetes, n (%)
a 0.265
<5 years 63 (12.9) 80 (14.9)
5–10 years 72 (14.7) 93 (17.4)
>10 years 354 (72.4) 363 (67.7)
Deep ulcer, n (%)
a 266 (52.7) 200 (35.8) <0.001
Size of ulcer, n (%)
a 0.002
<1 cm
2 173 (34.4) 219 (39.5)
1–5c m
2 259 (51.5) 294 (53.0)
>5 cm
2 71 (14.2) 42 (7.5)
Duration of ulcer, n (%)
a <0.001
<1 week 58 (11.5) 120 (21.7)
1 week–3 months 296 (58.0) 318 (57.5)
>3 months 148 (29.5) 115 (20.8)
Plantar location, n (%)
a 197 (40.9) 284 (55.0) <0.001
Pretibial oedema, n (%)
a 111 (22.0) 83 (14.9) 0.002
Heart failure NYHA III–IV, n (%)
a 64 (12.7) 47 (8.5) 0.027
Neurological disorder, n (%)
a 40 (8.0) 27 (4.9) 0.039
Inability to stand or walk without help, n (%)
a 65 (12.9) 36 (6.5) <0.001
Visual impairment, n (%)
a 89 (17.9) 66 (12.0) 0.007
ESRD, n (%)
a 35 (7.0) 25 (4.5) 0.082
Polyneuropathy, n (%)
a 383 (77.2) 424 (79.3) 0.429
Infection, n (%)
a 293 (60.9) 282 (53.4) 0.016
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OR 2.82, CI 1.88–4.22, p<0.001 in unadjusted analyses
(Fig. 1) vs OR 1.87, CI 1.20–2.91, p<0.001 after adjust-
ments for the other variables included in the predictive
model.
Discussion
The EURODIALE study is one of the few large prospec-
tive, international studies on outcome and determinants of
outcome in diabetic foot disease. Despite the severity of
Predictor variables Outcome: healing
OR 95% CI p value
Age, per 10 year increase 1.32 1.17–1.49 <0.001
Sex, men vs women 1.50 1.07–1.97 0.018
Duration of diabetes 0.712
5–10 vs <5 years
a 0.96 0.56–1.65
>10 vs <5 years
a 1.05 0.69–1.60
Depth of ulcer, deep vs superficial 1.66 1.25–2.20 <0.001
Size of ulcer <0.001
1–5v s< 1c m
2a 2.25 1.60–3.17
>5 vs <1 cm
2a 4.22 2.64–6.72
Duration of ulcer <0.001
1 week to 3 months vs <1 week
a 1.81 1.15–2.85
>3 months vs <1 week
a 2.61 1.60–4.27
Location, plantar vs non-plantar 0.73 0.55–0.98 0.035
Pretibial oedema, yes vs no 1.79 1.27–2.51 0.001
Heart failure (NYHA III–IV), yes vs no 2.03 1.35–3.05 0.001
Neurological disorder, yes vs no 1.44 0.85–2.46 0.176
Inability to stand or walk without help, yes vs no 2.50 1.62–3.79 <0.001
Visual impairment, yes vs no 1.36 0.94–1.98 0.105
ESRD, yes vs no 2.20 1.30–3.73 0.004
Polyneuropathy, yes vs no 1.41 0.98–2.04 0.065
Infection, yes vs no 1.47 1.09–2.00 0.012
PAD, yes vs no 2.31 1.72–3.10 <0.001
Table 3 Association of each
potential predictor with
non-healing in the overall
population (n=1,088)
aReference category
Table 4 Multivariable models with independent predictors of non-healing in the whole study population and in patients with and without PAD
Variable All patients Patients with PAD Patients without PAD
OR 95% CI p value OR 95% CI p value OR 95% CI p value
Age, per 10 year increase 1.28 1.11–1.47 0.001 1.42 0.17–1.73 <0.001 1.55 0.91–2.63 0.105
Sex, men vs women 1.72 1.23–2.40 0.002 1.97 1.25–3.11 0.003 –– –
Size of ulcer <0.001 <0.001 0.008
1–5v s< 1c m
2a 2.26 1.58–3.22 3.22 1.95–5.32 1.25 0.74–2.12
>5 vs <1 cm
2a 3.88 2.37–6.34 3.84 1.97–7.48 3.48 1.62–7.46
Duration of ulcer ––0.086
1 week to 3 months vs <1 week
a –– –– 2.14 1.05–4.36
>3 months vs <1 week
a –– –– 2.18 0.98–4.84
Heart failure (NYHA III–IV), yes vs no 1.55 0.99–2.43 0.054 1.54 0.87–2.74 0.141 –– –
Inability to stand or walk without help, yes vs no 2.00 1.27–3.14 0.003 2.36 1.34–4.17 0.003 1.91 0.86–4.24 0.112
ESRD, yes vs no 2.51 1.41–4.48 0.002 3.04 1.38–6.70 0.006 2.00 0.76–5.25 0.161
Polyneuropathy, yes vs no 1.42 0.96–2.08 0.078 –– – 1.70 0.89–3.25 0.108
Infection, yes vs no –– – 1.63 1.03–2.58 0.036 –– –
PAD, yes vs no 1.71 1.23–2.37 0.001 N/A N/A
aReference category
N/A, not applicable
752 Diabetologia (2008) 51:747–755the underlying disease and the important co-morbidity [7],
clinical outcome of this population within a 1 year follow-
up can be considered favourable. In our cohort, 77% of the
patients healed (with or without a minor amputation), 5%
underwent a major amputation and 6% died. However,
healing rates in patients with PAD were considerably
worse. In addition, predictors of healing also differed
between the groups with and without PAD. The presence
of infection, which is generally regarded as an important
predictor of healing, was only predictive in individuals
with PAD.
With regard to the overall outcome in our cohort, two recent
studies found relatively comparable outcomes. Jeffcoate et al.
[18] reported healing (excluding minor amputations) rates of
66% and an amputation rate of 5% with a similar prevalence
of PAD. In a German cohort, Beckert et al. [19] found healing
rates between 57% and 93% and major amputation rates of
3%, although the data as presented in that report cannot be
easily compared because of their unique classification system.
Oyibo et al. [20] also found similar rates of major amputation
in their cohort (5%).
Our study shows that the combination of PAD and
infection has a major impact on healing rates (Fig. 1); this
significant interaction between PAD and infection is, in our
opinion, one of the major findings of this study. In the
patients without PAD we did not observe an association
between infection and non-healing, which suggests that in
these patients current antibiotic regimens and surgical
techniques seem adequate to save a limb with adequate
perfusion. However, within the total population of individ-
uals with diabetic foot disease in developed countries, the
group of infected and ischaemic ulcers accounted for almost
one-third of all patients in our earlier report [7]. In a recent
study, a significant relation between PAD, infection and poor
outcome was also observed: in that study’s large cohort of
outpatients with type 2 diabetes, PAD was an independent
predictor of infection-related mortality [21]. Unfortunately,
there is very little insight into the pathophysiology and
treatment of infection in individuals with PAD. Currently it
is not clear why infection is more prevalent and more
difficult to treat in individuals with PAD. Remarkably, very
few patients with PAD were included in most of the
randomised trials on antibiotic therapy in diabetic foot
infections [22, 23]. It has previously been demonstrated that
lower limb tissue levels of antibiotics can be markedly
decreased as a result of impaired perfusion in PAD [24]. It is
open to speculation whether aggressive revascularisation will
improve control of infection in these patients.
Although some earlier studies have examined the impact
of co-morbidities on ulcer healing [25], no studies, to our
knowledge, have systematically assessed in a multivariable
analysis the effects on ulcer healing of patient characteristics
including co-morbidities, as well as foot and ulcer character-
istics at baseline. In our study, older age, ulcer size and
several co-morbidities were independent predictors of non-
healing in patients with and without PAD. Recently a
number of larger studies reported data on determinants of
outcome in diabetic foot disease such as the single-centre
study by Beckert in Germany and the UK multi-centre study
initiated by Jeffcoate [19, 26]. The former focused on
wound-based characteristics and also found that the pres-
ence of PAD (defined as absence of pedal pulses) was an
independent predictor of outcome (healing), while infection
was not. In the recent UK multi-centre study, ulcer area was
a strong predictor of outcome, as was the presence of PAD;
co-morbidities were not taken into account in the regression
analyses. Surprisingly, depth of the ulcer was not associated
with outcome in our multivariable model, a finding also
shown by Ince et al. [26]. In a retrospective study, Miyajima
et al. [27] reported on patient characteristics that determined
major lower extremity amputation and found that haemo-
dialysis was an independent predictor of major amputation;
in this study wound characteristics were not part of the
regression analyses. The poor prognosis of foot ulcers for
individuals in our study with ESRD is in line with earlier
reports, in which amputation rates of 57% in individuals on
haemodialysis were observed [25]. Although in our study
ESRD was a predictor of non-healing in patients with and
without PAD, it seemed to have a particularly negative effect
in the latter patient group. PAD is frequently diagnosed and
associated with adverse outcomes in haemodialysis patients
[28]. PAD in ESRD patients is more severe and is
accompanied by diffuse vascular calcifications, involvement
of both distal infrapopliteal and foot arteries, and by
impaired microcirculatory perfusion [29–31]. The severity
of PAD in ESRD may explain the importance of ESRD in
our healing models; additional mechanisms are probably
impaired host defences in chronic renal failure and uraemia,
or the presence of more resistant micro-organisms [32, 33].
The outcome of patients without PAD in our study was
relatively favourable: 84% of the patients healed with or
without minor amputation, 2% underwent a major amputa-
tion and 3% died. In our multivariate models, loss of
sensation was associated with a poorer outcome in these
patients, suggesting that loss of protective sensation is not
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Diabetologia (2008) 51:747–755 753only a key factor in the development of an ulcer, but also
affects its outcome. This may be related to the preserved
mechanism of off-loading the ulcer in individuals with intact
protective sensation. However, neuropathy may also have
direct effects on wound healing. Although data on the effect
of neuropathy on wound healing in humans are scarce, some
animal studies suggest that denervation may contribute to
impaired wound healing in diabetes [34, 35]. A large dataset
on individuals with neuropathic ulcers comes from retro-
spective database analyses in which healing rates of 47%
were observed [36]. Although this study reported on
healing at 20 weeks (whereas the current one examined
healing rates at 1 year), the different results compared with
our study are striking and may be related to an increased
awareness of the importance of adequate off-loading, as a
result of publication of international guidelines and reports
on casting techniques [37–39].
There are several limitations to our study.Individualswho
were lost to follow-up were excluded from the analyses as
healing status could not be obtained; these individuals were
slightly older and had a greater incidence of heart failure,
deep ulcers or ulcers with a longer duration and PAD at
baseline. In addition, we excluded patients who had had a
previous ulcer within 12 months prior to presentation (i.e. we
probably excluded patients with recurrent ulcers). Also we
excluded patients with a life expectancy shorter than 1 year
because of anticipated problems with follow-up. The
estimates obtained in our models may therefore have under-
estimated the probability of non-healing in patients with a
recurrentfoot ulcer,although in one earlier study healing rate
of neuropathic foot ulcers did not decrease in patients with
multiple recurrences [40]. Since our study was embedded in
daily clinical practice, limitations had to be set with regard
to the number and type of data collected. It was therefore
not possible to record more characteristics of these patients
such as medication and extensive documentation of all
complications. Moreover, to facilitate data collection, some
continuous data (e.g. ulcer size) had to be transformed into
a limited set of categories. Nevertheless, the set of potential
predictors used in the present study do cover relevant
patient and disease-specific aspects that can be easily
assessed and used for patient risk estimation in clinical
practice. Finally, our predictive model is based on outcomes
that can be obtained in developed countries with access to
the necessary resources such as antibiotic treatment and
revascularisation; our results, therefore, are most relevant
for diabetic foot ulcer patients in developed countries.
In conclusion, the results of this study have several
implications. Both ulcer characteristics and several patient-
related characteristics affected the outcome of diabetic foot
ulcers. Therefore, a holistic approach by healthcare profes-
sionals who are familiar with the treatment of complicated
diabetic patients is essential in order to identify the high-risk
patient and start appropriate treatment. We found that
patients with and without PAD differ in clinical character-
istics, outcome and predictors of outcome. Taking into
account these findings and the different pathophysiology
and treatment of PAD and non-PAD ulcers, we feel that that
diabetic foot ulcer with and without PAD should be defined
as two separate disease states. The prevalent combination of
PAD and infection is a unique entity; an important challenge
lies in the development of evidence-based strategies to
improve the poor outcome of these patients. Both studies
comparing different antibiotic regimens in PAD, and studies
evaluating the effects of early revascularisation on control of
infection are urgently needed.
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